Peptide therapy sits at the intersection of regenerative medicine, metabolic health, and patient demand for proactive, personalized care. However, rapidly evolving FDA regulatory shifts, the proliferation of gray-market "Research Use Only" (RUO) compounds, and unclear diagnostic frameworks leave clinicians unsure of how to incorporate these modalities safely and profitably.

In this webinar, Andy Triggs equips clinicians and practice leaders with a comprehensive roadmap to evaluate, implement, and scale peptide therapies within a compliant cash-pay or hybrid practice model.

What You’ll Take Away

In this session, we shift the diagnostic focus from reactive disease detection to proactive, outcome-based medicine. 

You'll learn:

• Navigate the Regulatory Environment: Differentiate  compounding rules, FDA Category status shifts, and the legal liabilities surrounding RUO vendors versus legitimate compounding pharmacies.

• Apply Diagnostic Biomarker Frameworks: Implement pre-treatment baseline panels and post-treatment monitoring protocols using targeted lab testing to ensure patient safety and quantify outcomes.

• Master Clinical Application & Safety: Identify primary clinical indications (GLP-1/GIP metabolic modulators, GH secretagogues, tissue recovery, and immune-modulating peptides) while minimizing contraindications and adverse events.

• Deploy a Profitable Business Model: Structure cash-pay pricing, package protocols with lab testing, and drive long-term patient retention through measurable clinical progress.